Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
New data from the FLAURA2 trial suggests a promising but complex treatment landscape for EGFR-mutated advanced NSCLC. Physicians should weigh the significant PFS benefits against the increased risk of adverse events before considering this combination as a first-line treatment option.
Oncology, Medical September 19th 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS